$2.09
6.63% yesterday
Nasdaq, Aug 12, 10:15 pm CET
ISIN
US69012T2069
Symbol
OTLK

Outlook Therapeutics, Inc. Stock price

$2.09
-0.23 9.91% 1M
+0.35 20.11% 6M
+0.20 10.58% YTD
-5.42 72.17% 1Y
-21.91 91.29% 3Y
-25.11 92.32% 5Y
-681.11 99.69% 10Y
-681.11 99.69% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.13 6.63%
ISIN
US69012T2069
Symbol
OTLK
Industry

Key metrics

Basic
Market capitalization
$84.0m
Enterprise Value
$109.5m
Net debt
$25.5m
Cash
$7.6m
Shares outstanding
32.9m
Valuation (TTM | estimate)
P/E
2.9 | negative
P/S
- | 12.0
EV/Sales
- | 15.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-251.7%
Return on Equity
102.7%
ROCE
1,339.3%
ROIC
-5,779.4%
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$0.0 | $7.0m
EBITDA
$-76.8m | -
EBIT
$-76.9m | $-56.1m
Net Income
$20.7m | $-36.3m
Free Cash Flow
$-64.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-28.4% | -
EBIT
-28.4% | 22.1%
Net Income
113.0% | 51.7%
Free Cash Flow
-9.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -516.7%
Free Cash Flow
-
More
EPS
$0.7
FCF per Share
$-1.9
Short interest
5.8%
Employees
23
Rev per Employee
$0.0
Show more

Is Outlook Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Outlook Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Outlook Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 39 39
50% 50%
-
- Research and Development Expense 38 38
11% 11%
-
-77 -77
28% 28%
-
- Depreciation and Amortization 0.12 0.12
50% 50%
-
EBIT (Operating Income) EBIT -77 -77
28% 28%
-
Net Profit 21 21
113% 113%
-

In millions USD.

Don't miss a Thing! We will send you all news about Outlook Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Outlook Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the 8 th Annual OIS Retina Innovation Summit being held on July 29, 2025 in Long Beach CA.
Neutral
GlobeNewsWire
21 days ago
Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, newly appointed Chief Executive Officer, participated in the Virtual Investor “What's Your Story” Summer Spotligh...
Neutral
GlobeNewsWire
about one month ago
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies
More Outlook Therapeutics, Inc. News

Company Profile

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.

Head office United States
CEO Lawrence Kenyon
Employees 23
Founded 2010
Website outlooktherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today